Literature DB >> 9133508

Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

J S Gottdiener1, D J Reda, B M Massie, B J Materson, D W Williams, R J Anderson.   

Abstract

BACKGROUND: Antihypertensive drugs may differ in their ability to reduce LV mass. Covariates other than drug selection, such as pretreatment LV mass, body weight, the magnitude of blood pressure reduction, race, and age may modify the response of LV mass to therapy. METHODS AND
RESULTS: Patients with mild to moderate hypertension (diastolic blood pressure, 95 to 109 mm Hg) were randomly allocated to treatment with atenolol, captopril, clonidine, diltiazem, hydrochlorothiazide, or prazosin in a double-masked trial. Patients achieving the goal diastolic blood pressure of <90 mm Hg during drug titration entered a 1-year maintenance period. Longitudinal analysis examined changes from baseline echocardiogram in LV mass at 8 weeks and at 1 year, statistically adjusted for pretreatment LV mass, systolic blood pressure, body weight, sodium excretion, physical activity, race, and age. Significant reductions at 1 year in adjusted LV mass were seen for patients in the highest tertile of pretreatment LV mass treated with hydrochlorothiazide (mean, -42.9; 95% confidence limits, -65.5, -20.2 g), captopril (mean, -38.7; 95% confidence limits, -61.0, -16.4 g), and atenolol (mean, -28.1; 95% confidence limits, -50.9, -5.3 g). These treatment effects differed from those of prazosin, diltiazem, or clonidine.
CONCLUSIONS: Antihypertensive drugs have disparate effects on LV mass independent of the magnitude of blood pressure reduction. Patients with adequate blood pressure control on captopril, hydrochlorothiazide, and atenolol show a reduction of LV mass after 1 year of treatment, whereas patients on diltiazem, clonidine, or prazosin do not.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9133508     DOI: 10.1161/01.cir.95.8.2007

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  43 in total

Review 1.  Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

Authors:  D J Sheridan; M P Kingsbury; N A Flores
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

Review 2.  Epidemiology of risk factors for hypertension: implications for prevention and therapy.

Authors:  M Kornitzer; M Dramaix; G De Backer
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 3.  Why beta-blockers are not cardioprotective in elderly patients with hypertension.

Authors:  Ehud Grossman; Franz H Messerli
Journal:  Curr Cardiol Rep       Date:  2002-11       Impact factor: 2.931

4.  Carvedilol inhibits right ventricular hypertrophy induced by chronic hypobaric hypoxia.

Authors:  L Tual; O-E Morel; F Favret; M Fouillit; C Guernier; A Buvry; L Germain; G Dhonneur; J-F Bernaudin; J-P Richalet
Journal:  Pflugers Arch       Date:  2006-04-26       Impact factor: 3.657

Review 5.  Regression of left ventricular hypertrophy is a key goal of hypertension management.

Authors:  Rubin Zhang; Judy Crump; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

Review 6.  Antihypertensive therapy in the prevention of stroke: what, when and for whom?

Authors:  M D Fotherby; B Panayiotou
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

7.  Effect of telmisartan on the regression of the left ventricular hypertrophy in the patients of essential hypertension.

Authors:  Kumar Haraprasad Misra; Mangala Charana Das; Y Roja Ramani
Journal:  J Clin Diagn Res       Date:  2013-07-01

8.  Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).

Authors:  Elsayed Z Soliman; Walter T Ambrosius; William C Cushman; Zhu-Ming Zhang; Jeffrey T Bates; Javier A Neyra; Thaddeus Y Carson; Leonardo Tamariz; Lama Ghazi; Monique E Cho; Brian P Shapiro; Jiang He; Lawrence J Fine; Cora E Lewis
Journal:  Circulation       Date:  2017-05-16       Impact factor: 29.690

Review 9.  Antihypertensive drugs and the heart.

Authors:  Joseph A Diamond; Robert A Phillips
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

10.  Secular trends in echocardiographic left ventricular mass in the community: the Framingham Heart Study.

Authors:  Bernhard M Kaess; Philimon Gona; Martin G Larson; Susan Cheng; Jayashree Aragam; Satish Kenchaiah; Emelia J Benjamin; Ramachandran S Vasan
Journal:  Heart       Date:  2013-09-16       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.